{"schema_version":"secwatch.filing_event.v1","accession":"0001110803-25-000057","form_type":"8-K","ticker":"ILMN","cik":"0001110803","company_name":"ILLUMINA, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.366304+00:00","generated_at":"2026-05-17T22:09:09.461321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Illumina Q2 EPS $1.19 non-GAAP, revenue $1.06B; raises FY2025 guidance","bullets":["Revenue $1.059B down 3% YoY; GAAP EPS $1.49, non-GAAP EPS $1.19 vs. $1.09 prior year.","FY2025 guidance raised: revenue decline (2.5%)-(0.5%), non-GAAP op margin 22%-22.5%, EPS $4.45-$4.55.","Repurchased 4.5M shares for $380M at avg $84.66; ~$800M remaining authorization.","Signed definitive agreement to acquire SomaLogic from Standard BioTools; close expected H1 2026.","Q2 free cash flow $204M; cash and short-term investments $1.16B."],"urls":{"canonical":"https://secwatch.observer/filing/0001110803-25-000057","json":"https://secwatch.observer/filing/0001110803-25-000057.json","markdown":"https://secwatch.observer/filing/0001110803-25-000057.md","text":"https://secwatch.observer/filing/0001110803-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1110803/000111080325000057/0001110803-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1110803/000111080325000057/ilmn-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:09:09.461321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}